Summary & Overview
CPT 78072: Parathyroid Nuclear Medicine Imaging with SPECT/CT Localization
CPT code 78072 identifies a specialized nuclear medicine procedure for parathyroid imaging that uses two different radiopharmaceuticals, SPECT imaging, and CT correlation to localize abnormal parathyroid tissue prior to surgery. This dual-tracer, multimodality approach improves anatomic localization and can include subtraction techniques to enhance detection. Nationally, 78072 is important for preoperative planning in primary and secondary hyperparathyroidism and impacts surgical workflow and imaging center utilization.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose and procedural components of 78072, common payer coverage considerations, expected sites of service, and operational implications for radiology and nuclear medicine practices. The publication also outlines benchmark themes such as utilization patterns, coding nuances for combined SPECT/CT studies, and relevant policy updates that influence prior authorization and medical necessity determinations.
This summary provides clinicians, billers, and policy analysts with the clinical context and payer landscape needed to understand where 78072 fits in the imaging pathway for parathyroid disease and what to expect from national payers regarding coverage and preoperative localization workflows.
Billing Code Overview
CPT code 78072 describes a nuclear medicine parathyroid imaging study that acquires sets of planar images after administration of small amounts of two different radiopharmaceuticals. The study includes comparison of those tracer images with single-photon emission computed tomography (SPECT) images and correlation with computed tomography (CT) for precise preoperative localization of abnormal parathyroid tissue. A subtraction study may be performed in some cases to improve detection of abnormal glands.
-
Service type: Nuclear medicine parathyroid imaging with dual-tracer comparison,
SPECTandCTcorrelation -
Typical site of service: Outpatient imaging center or hospital radiology/nuclear medicine department
Clinical & Coding Specifications
Clinical Context
A 56-year-old patient with biochemical evidence of primary hyperparathyroidism (elevated serum calcium and parathyroid hormone) is referred for preoperative localization prior to parathyroidectomy. The nuclear medicine physician administers small amounts of two radiopharmaceuticals (commonly Tc-99m sestamibi and a second tracer) and acquires sets of planar images, performs SPECT imaging, and fuses those images with CT for precise anatomic localization. A subtraction study may be performed when dual-tracer imaging is required to differentiate thyroid from parathyroid uptake. The workflow includes patient check-in and IV placement, tracer administration, timed imaging at multiple phases, SPECT/CT acquisition, optional subtraction image processing, image interpretation by the radiologist/nuclear medicine physician, and generation of a diagnostic report for the surgical team documenting suspected adenoma location(s) and recommended surgical approach.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation of the imaging study separate from technical services |
TC | Technical component | Use when billing only the facility/technical component (scanner, technologist, radiopharmaceutical) |